vs

Side-by-side financial comparison of HERON THERAPEUTICS, INC. (HRTX) and SUNation Energy, Inc. (SUNE). Click either name above to swap in a different company.

HERON THERAPEUTICS, INC. is the larger business by last-quarter revenue ($40.6M vs $27.2M, roughly 1.5× SUNation Energy, Inc.). SUNation Energy, Inc. runs the higher net margin — 9.6% vs -7.3%, a 16.8% gap on every dollar of revenue. On growth, SUNation Energy, Inc. posted the faster year-over-year revenue change (77.0% vs -0.5%). Over the past eight quarters, SUNation Energy, Inc.'s revenue compounded faster (43.5% CAGR vs 8.2%).

Antibe Therapeutics was a Toronto-based pharmaceutical company that develops pain and inflammation-reducing drugs based on gaseous mediator technology. Antibe was founded by John L. Wallace, also a co-founder of NicOx, the first company to develop drugs utilizing gaseous mediators. Founded in 2009, the company listed on the TSX Venture Exchange in 2013 and was moved to the Toronto Stock Exchange in November 2020. In 2015, Antibe acquired Citagenix, a distributor involved in regenerative medic...

Suncor Energy Inc. is a Canadian integrated energy company based in Calgary, Alberta. It specializes in production of synthetic crude from oil sands. In the 2020 Forbes Global 2000, Suncor Energy was ranked as the 48th-largest public company in the world.

HRTX vs SUNE — Head-to-Head

Bigger by revenue
HRTX
HRTX
1.5× larger
HRTX
$40.6M
$27.2M
SUNE
Growing faster (revenue YoY)
SUNE
SUNE
+77.5% gap
SUNE
77.0%
-0.5%
HRTX
Higher net margin
SUNE
SUNE
16.8% more per $
SUNE
9.6%
-7.3%
HRTX
Faster 2-yr revenue CAGR
SUNE
SUNE
Annualised
SUNE
43.5%
8.2%
HRTX

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
HRTX
HRTX
SUNE
SUNE
Revenue
$40.6M
$27.2M
Net Profit
$-3.0M
$2.6M
Gross Margin
72.6%
40.7%
Operating Margin
0.1%
10.7%
Net Margin
-7.3%
9.6%
Revenue YoY
-0.5%
77.0%
Net Profit YoY
-180.6%
138.2%
EPS (diluted)
$-0.01
$105.59

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
HRTX
HRTX
SUNE
SUNE
Q4 25
$40.6M
$27.2M
Q3 25
$38.2M
$19.0M
Q2 25
$37.2M
$13.1M
Q1 25
$38.9M
$12.6M
Q4 24
$40.8M
$15.4M
Q3 24
$32.8M
$14.7M
Q2 24
$36.0M
$13.5M
Q1 24
$34.7M
$13.2M
Net Profit
HRTX
HRTX
SUNE
SUNE
Q4 25
$-3.0M
$2.6M
Q3 25
$-17.5M
$-393.0K
Q2 25
$-2.4M
$-9.6M
Q1 25
$2.6M
$-3.5M
Q4 24
$3.7M
$-6.8M
Q3 24
$-4.8M
$-3.3M
Q2 24
$-9.2M
$-6.9M
Q1 24
$-3.2M
$1.2M
Gross Margin
HRTX
HRTX
SUNE
SUNE
Q4 25
72.6%
40.7%
Q3 25
68.8%
38.0%
Q2 25
73.5%
37.0%
Q1 25
78.3%
35.1%
Q4 24
74.9%
36.4%
Q3 24
71.2%
35.6%
Q2 24
70.8%
35.4%
Q1 24
75.6%
36.4%
Operating Margin
HRTX
HRTX
SUNE
SUNE
Q4 25
0.1%
10.7%
Q3 25
-10.7%
-1.3%
Q2 25
-4.4%
-16.6%
Q1 25
8.1%
-17.2%
Q4 24
10.2%
-42.3%
Q3 24
-13.6%
-10.9%
Q2 24
-17.9%
-15.0%
Q1 24
-13.8%
-16.5%
Net Margin
HRTX
HRTX
SUNE
SUNE
Q4 25
-7.3%
9.6%
Q3 25
-45.8%
-2.1%
Q2 25
-6.4%
-73.5%
Q1 25
6.8%
-27.7%
Q4 24
9.0%
-44.4%
Q3 24
-14.8%
-22.4%
Q2 24
-25.6%
-51.2%
Q1 24
-9.1%
9.1%
EPS (diluted)
HRTX
HRTX
SUNE
SUNE
Q4 25
$-0.01
$105.59
Q3 25
$-0.10
$-0.12
Q2 25
$-0.02
$-3.14
Q1 25
$0.01
$-106.71
Q4 24
$0.02
$41676.94
Q3 24
$-0.03
$-2350.12
Q2 24
$-0.06
$-11022.91
Q1 24
$-0.02
$-38414.84

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
HRTX
HRTX
SUNE
SUNE
Cash + ST InvestmentsLiquidity on hand
$28.6M
$7.2M
Total DebtLower is stronger
$6.6M
Stockholders' EquityBook value
$14.3M
$24.3M
Total Assets
$255.9M
$48.2M
Debt / EquityLower = less leverage
0.27×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
HRTX
HRTX
SUNE
SUNE
Q4 25
$28.6M
$7.2M
Q3 25
$43.1M
$5.4M
Q2 25
$16.5M
$3.2M
Q1 25
$19.3M
$1.4M
Q4 24
$25.8M
$839.3K
Q3 24
$25.7M
$1.1M
Q2 24
$18.4M
$1.0M
Q1 24
$20.4M
$1.8M
Total Debt
HRTX
HRTX
SUNE
SUNE
Q4 25
$6.6M
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
Stockholders' Equity
HRTX
HRTX
SUNE
SUNE
Q4 25
$14.3M
$24.3M
Q3 25
$14.9M
$21.7M
Q2 25
$-27.3M
$22.1M
Q1 25
$-28.5M
$14.8M
Q4 24
$-33.7M
$8.5M
Q3 24
$-40.0M
$13.1M
Q2 24
$-37.9M
$-10.9M
Q1 24
$-33.8M
$-11.2M
Total Assets
HRTX
HRTX
SUNE
SUNE
Q4 25
$255.9M
$48.2M
Q3 25
$248.9M
$49.6M
Q2 25
$232.1M
$44.1M
Q1 25
$235.8M
$44.4M
Q4 24
$233.1M
$45.7M
Q3 24
$220.8M
$51.0M
Q2 24
$218.1M
$52.9M
Q1 24
$217.9M
$54.7M
Debt / Equity
HRTX
HRTX
SUNE
SUNE
Q4 25
0.27×
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
HRTX
HRTX
SUNE
SUNE
Operating Cash FlowLast quarter
$-9.2M
$2.1M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
0.0%
Cash ConversionOCF / Net Profit
0.81×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
HRTX
HRTX
SUNE
SUNE
Q4 25
$-9.2M
$2.1M
Q3 25
$1.3M
$2.4M
Q2 25
$-10.9M
$-130.2K
Q1 25
$-8.9M
$-3.4M
Q4 24
$-11.8M
$-1.9M
Q3 24
$3.4M
$-968.1K
Q2 24
$-4.6M
$-776.4K
Q1 24
$-9.5M
$-2.6M
Free Cash Flow
HRTX
HRTX
SUNE
SUNE
Q4 25
Q3 25
$2.4M
Q2 25
$-11.1M
Q1 25
$-9.0M
Q4 24
$-1.9M
Q3 24
$2.9M
$-980.3K
Q2 24
$-788.4K
Q1 24
$-2.7M
FCF Margin
HRTX
HRTX
SUNE
SUNE
Q4 25
Q3 25
12.5%
Q2 25
-29.8%
Q1 25
-23.1%
Q4 24
-12.4%
Q3 24
9.0%
-6.7%
Q2 24
-5.8%
Q1 24
-20.1%
Capex Intensity
HRTX
HRTX
SUNE
SUNE
Q4 25
0.0%
Q3 25
0.0%
0.0%
Q2 25
0.6%
Q1 25
0.3%
Q4 24
0.0%
Q3 24
1.3%
0.1%
Q2 24
0.1%
Q1 24
0.0%
Cash Conversion
HRTX
HRTX
SUNE
SUNE
Q4 25
0.81×
Q3 25
Q2 25
Q1 25
-3.37×
Q4 24
-3.22×
Q3 24
Q2 24
Q1 24
-2.20×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

HRTX
HRTX

CINVANTI$22.9M56%
ZYNRELEF$12.5M31%
Aponvie$3.8M9%
SUSTOL$1.3M3%

SUNE
SUNE

Transferred At Point In Time$15.1M55%
Hawaii Energy Connection$10.0M37%
Transferred Over Time$2.1M8%

Related Comparisons